Dianthus Therapeutics, Inc. Common Stock (DNTH)
Dianthus Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for rare and life-threatening diseases. The company utilizes innovative approaches in protein engineering and drug discovery to create treatments that address unmet medical needs, particularly in the fields of hematology and immunology. Founded with the goal of advancing precision medicine, Dianthus aims to improve patient outcomes through its specialized therapeutics.
Company News
Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional fusion protein targeting autoimmune diseases. The agreement involves up to $38 million in initial payments and potential milestone payments up to $962 million, with Dianthus gaining global rights outside Greater China.
Ratings for Dianthus Therapeutics (NASDAQ:DNTH) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewh...
American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation are part of the Zacks top Analyst Blog.